A new facility for psychedelics research, the Center for Psychedelic Psychotherapy and Trauma Research, was recently opened in New York City. The center follows a multifaceted research and clinical approach to finding new and more effective treatments for anxiety, depression, PTSD and other conditions linked to stress in both the civilian and veteran populations. The facility’s research will center on the study of psilocybin, MDMA and other psychedelic substances.
MDMA, which is commonly known as ecstasy, is a psychoactive drug that may be used as a PTSD therapy treatment. Earlier in 2017, the U.S. FDA granted Breakthrough Therapy Designation status to MDMA-assisted psychotherapy. Currently, phase 3 trials on this psychoactive compound are in progress, despite the fact that MDMA has not yet been approved for clinical use.
MDMA-assisted therapy is a new method of treatment, and while preliminary clinical study results show promise, more information on the drug is required to ascertain how the therapy will work in individuals who have complicated mental health issues.
In addition to this research, the center will also conduct clinical trials needed for MDMA and other psychedelic-assisted therapy treatments to be adopted. The facility will also carry out extensive research on how these treatments affect a patient’s body. The information gathered will be used to help researchers scale and deliver these treatments in the way most effective to patients.
Rachel Yehuda, a professor of neuroscience and psychiatry, has been appointed the center’s head. Yehuda recently finished an MDMA-assisted psychotherapy clinician training been sponsored by MAPS (Multidisciplinary Association for Psychedelic Studies).
Yehuda stated that individuals who have undergone MDMA-assisted psychotherapy reported increased interpersonal trust, connectedness, and compassion towards others and self as well as feelings of introspection. She then explained that it was critical to listen to an individual’s subjective experiences with these psychoactive compounds then learn more about the therapeutic possibilities they possess through extensive clinical trials.
The center’s activities lie in four vital areas:
Dennis S. Carney, dean of Icahn School of Medicine at Mount Sinai, which established the facility, stated that under the leadership of Yehuda, the newly established facility would offer a better understanding of how psychedelic-assisted psychotherapy treatments work.
Things are also heating up in Canada within the psychedelics space. Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) has signed NDAs aimed at establishing research collaborations for the rapid development of products starting in Q4 2020.
NOTE TO INVESTORS: The latest news and updates relating to Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) are available in the company’s newsroom at https://ibn.fm/PULL
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
According to a recent study, individuals who have used classic psychedelics like LSD or psilocybin…
There is a growing trend in which parents take tiny doses of psychedelics like LSD…
Walter Reed National Military Medical Center officials confirmed they are awaiting a $4.9m grant to…
A new study has found that while all ethnic and racial groups can benefit from…
A new study that is yet to be peer-reviewed has found that rats given psilocybin…
The American embassy in Peru has warned Americans against taking traditional psychedelics like the ayahuasca…